Trending...
- How to Fast-Track Your Way to the Top with The Code
- Naperville Residents Invited to 'Chat with the Chief' on May 1
- Concert Violinist Addison Teng Redefines Music Education for a New Generation
TARRYTOWN, N.Y., May 1, 2025 ~ A new potential treatment for glioblastoma, a type of brain cancer, will be featured at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The treatment, called lucicebtide and formerly known as ST101, is being developed by Sapience Therapeutics, Inc., a clinical-stage biotechnology company.
The Phase 2 clinical trial of lucicebtide showed promising results in patients with glioblastoma. The drug works by targeting C/EBPβ, a protein that plays a role in both cancer growth and immune system regulation.
More on illi News
The data from the trial will be presented in an oral presentation by Dr. Fabio M. Iwamoto from the Division of Neuro-Oncology at New York-Presbyterian/Columbia University Irving Medical Center. The presentation is titled "Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization" and will take place on Saturday, May 31st at 3:00 pm CDT.
This new treatment has the potential to improve outcomes for patients with glioblastoma and offers hope for those battling this aggressive form of cancer. More information about the presentation can be found on the 2025 ASCO Annual Meeting website.
The Phase 2 clinical trial of lucicebtide showed promising results in patients with glioblastoma. The drug works by targeting C/EBPβ, a protein that plays a role in both cancer growth and immune system regulation.
More on illi News
- New Podcast "Change Cycle" Unpacks the Complexity of Driving Systemic Change Toward a Circular Economy
- Rkaydz Video Game Museum Launches "Acquisition Series"
- Coastguard Nelson (NZ) selects Omnitronics omnicore Express Dispatch - Completing their transition from analog to digital
- First Choice Neurology Partners with NeuroDiscovery AI to Advance Neurological Care and Research
- Is Billboard Advertising Still Effective in 2025?
The data from the trial will be presented in an oral presentation by Dr. Fabio M. Iwamoto from the Division of Neuro-Oncology at New York-Presbyterian/Columbia University Irving Medical Center. The presentation is titled "Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization" and will take place on Saturday, May 31st at 3:00 pm CDT.
This new treatment has the potential to improve outcomes for patients with glioblastoma and offers hope for those battling this aggressive form of cancer. More information about the presentation can be found on the 2025 ASCO Annual Meeting website.
Filed Under: Business
0 Comments
Latest on illi News
- Care Dental Implant & Cosmetic Center's New Website Launch!
- $4.3 Million Waiver Exemption Granted by FDA on New Drug Application Fee for Treatment Addressing Suicidal Depression, PTSD: NRx: Stock Symbol: NRXP
- YMCA Seeks to Expand Civic Leadership Opportunities for More New Jersey Youth
- Swim Stroke Doctor, Secures Patent for Groundbreaking Swim Cap That Improves Performance Through
- Anern Launches New Generation of Lithium Solar Batteries, Empowering a Smarter, Greener Future
- K2 Integrity and the Institute for Financial Integrity Launch AML/CFT Course for Investment Advisers
- Buttcoin - The Next Bitcoin Foundation Explores First Spot Buttcoin ($BUTTCOIN) ETP Listing on Switzerland's SIX Exchange
- Start Dogecoin cloud mining with XY Miners and maximize your passive income
- J INTS BIO Presents Research Results for Next-Generation Innovative Anticancer Therapeutics 'JIN-A02' and 'JIN-001' at AACR 2025
- New Report Highlights the Most Dangerous States for Transportation and Warehouse Workers
- City Of Chicago Joins Nationwide Coalition in Lawsuit to Challenge the Trump Administration's Unlawful Firing of Federal Employees
- Seecoin Expands Beyond Gaming: A Web3 (r)evolution for All Content Creators
- Barcelona-based Neurosurgical Specialist Awarded Designation of International Center of Excellence for Ehlers Danlos Syndrome
- Pregis Expands Multi-Layer Technology for High-Performance Barrier Films at Anderson Facility
- InventHelp Inventor Develops New Makeup Application Machine (CHK-1097)
- New Professional Association to Study Principles of Hospitality Applied to the Delivery of Healthcare
- Clinical Endpoints Successfully Met in Study for Groundbreaking 12-Lead ECG Synthesis Technology Allowing Software Application to FDA: HeartBeam, Inc
- DATA BREACH ALERT: Edelson Lechtzin LLP Is Investigating Claims On Behalf Of Medical Express Ambulance, Inc. Customers Whose Data May Have Been Compromised
- Boston Industrial Solutions, Inc. Unveils Natron® 504N UV LED Inks Designed for EPSON Printheads
- Kavelle Christie: Trump's First 100 Days Mark Alarming Breakdown in Healthcare, Public Health, and Freedoms